Your browser doesn't support javascript.
loading
Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.
Vitkauskaite, Monika; Vinikovas, Arturas; Miglinas, Marius; Rimsevicius, Laurynas; Cerkauskaite, Agne; Macioniene, Ernesta; Asakiene, Egle.
Affiliation
  • Vitkauskaite M; Faculty of Medicine Vilnius University Vilnius Lithuania.
  • Vinikovas A; Faculty of Medicine Vilnius University Vilnius Lithuania.
  • Miglinas M; Clinic of Gastroenterology, Nephro-Urology and Surgery Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania.
  • Rimsevicius L; Faculty of Medicine Vilnius University Vilnius Lithuania.
  • Cerkauskaite A; Clinic of Gastroenterology, Nephro-Urology and Surgery Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania.
  • Macioniene E; Faculty of Medicine Vilnius University Vilnius Lithuania.
  • Asakiene E; Clinic of Gastroenterology, Nephro-Urology and Surgery Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania.
Clin Case Rep ; 10(3): e05573, 2022 Mar.
Article in En | MEDLINE | ID: mdl-35317070
ABSTRACT
Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Aspects: Patient_preference Language: En Journal: Clin Case Rep Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline Aspects: Patient_preference Language: En Journal: Clin Case Rep Year: 2022 Document type: Article